Mogrify secures £8.3m in Series A funding led by Astellas Venture Management and Parkwalk Advisors
The financing will support the advancement of proprietary in vivo reprogramming therapies through pre-clinical translation.
Mogrify is a biopharmaceutical company developing in vivo reprogramming therapies to address degenerative conditions. Its proprietary platforms use big data and genomics to control human cell fate.
Mogrify has secured £8.3m in an additional Series A closing co-led by Astellas Venture Management and Parkwalk Advisors. The financing also drew participation from Ahren Innovation Capital, Trend Investment Group, and Jonathan Milner.
The capital will support the advancement of the company pipeline of in vivo reprogramming therapies through pre-clinical translation. Funds will also facilitate continued platform optimisation and new biopharmaceutical collaborations.
The latest capital injection follows a series of operational milestones and positions the enterprise to deliver developmental objectives ahead of a prospective Series B fundraise. The Cambridge-based business focuses on degenerative conditions affecting the eye, ear, and pancreas.
From the founder
"We are delighted to receive the continued support of Astellas Venture Management, Parkwalk Advisors and other existing investors as we relentlessly focus on progressing our novel pipeline of in vivo reprogramming therapies through pre-clinical translation. Aligned to a consolidated corporate structure and vision, this latest funding will provide sufficient cash runway to enable the achievement of key development milestones in both our internal programs as well as those being developed in collaboration with strategic partners. Existing investor commitment is a testament to our delivery of world-class science, expertise in cellular reprogramming and the unique potential of the MOGRIFY platform to deliver novel regenerative medicines to improve the lives of a broad spectrum of patients."
Darrin Disley
CEO at Mogrify
Investor perspective
"Mogrify has made significant progress in the development and commercialization of its technology and is uniquely positioned to address a rapidly growing regenerative medicine market."
Tadayoshi Hirata
Senior Investment Manager, Astellas Venture Management
Use of funds
- 01Continue product development
- 02Fund research and development
Investors
Tadayoshi Hirata
Astellas Venture Management
Alastair Kilgour
Parkwalk Advisors
Ahren Innovation Capital
Trend Investment Group
